HIV-1 infection impairs HSV-specific CD4 + and CD8 + T-cell response by reducing Th1 cytokines and CCR5 ligand secretion

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 9-17

  Rubbo, Pierre Alain ^a,b,c   Tuaillon, Edouard ^a,b,c   Nagot, Nicolas ^a,b,c   Chentoufi, Aziz Alami ^d   Bolloré, Karine ^a,b,c   Reynes, Jacques ^c   Vendrell, Jean Pierre ^a,b,c   Benmohamed, Lbachir ^d,e   Van De Perre, Philippe ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b UMR 1058 University of Montpellier   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CCR5 ligands; HIV 1 infection; HSV glycoprotein D peptide epitopes; T cell immunity; Viral synergy

Indexed keywords

CHEMOKINE RECEPTOR CCR5; EOTAXIN; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN D; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOKINE; RANTES; CYTOKINE; LIGAND; VIRUS PROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSPOT ASSAY; ERROR; FEMALE; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MIXED INFECTION; MOLECULAR WEIGHT; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; VIRUS REPLICATION; HERPES SIMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SIMPLEXVIRUS; VIROLOGY;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOWN-REGULATION; EPITOPES; FEMALE; HERPES SIMPLEX; HIV INFECTIONS; HIV-1; HUMANS; LIGANDS; MALE; MIDDLE AGED; RECEPTORS, CCR5; SIMPLEXVIRUS; TH1 CELLS; VIRAL PROTEINS;

EID: 79960727101     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318224d0ad     Document Type: Article

References (38)

1. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis. 2004;190:693-696. (Pubitemid 39049997)
2. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. 2008;198:241-249. (Pubitemid 352035760)
3. Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis. 2003;36:207-211. (Pubitemid 36143420)
4. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-439.
5. Nagot N, Ouedraogo A, Foulongne F, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007;356:790-799. (Pubitemid 46294611)
6. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS. 2006;20:2305-2313. (Pubitemid 44789532)
7. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445. (Pubitemid 38420652)
8. Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis. 2008;8:490-497. (Pubitemid 352005823)
9. Dasgupta G, Nesburn AB, Wechsler SL, et al. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol. 2010;5:1-4.
10. Dasgupta G, Chentoufi AA, Nesburn AB, et al. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines. 2009;8:1023-1035.
11. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009;15:886-892.
12. Lingappa JR, Baeten JM, Wald A, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010;375:824-833.
13. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis. 2006;43:347-356. (Pubitemid 44078908)
14. *0201- restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol. 2008;180:426-437.
15. Ben Mohamed L, Bertrand G, McNamara CD, et al. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol. 2003;77:9463-9473. (Pubitemid 37011042)
16. Zhang X, Castelli FA, Zhu X, et al. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin Vaccine Immunol. 2008;15:1436-1449.
17. Harari A, Vallelian F, Meylan PR, et al. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174:1037-1045. (Pubitemid 40094300)
18. Ramaswamy M, Waters A, Smith C, et al. Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2007;195:410-415. (Pubitemid 46146119)
19. Bettahi I, Zhang X, Afifi RE, et al. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dentritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 2006;19:220-236. (Pubitemid 44050321)
20. Sin JI, Kim JJ, Boyer JD, et al. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol. 1999;73:501-509. (Pubitemid 28565395)
21. Sloan DD, Jerome KR. Herpes simplex virus remodels T-cell receptor signaling, resulting in p38-dependent selective synthesis of interleukin-10. J Virol. 2007;81:12504-12514. (Pubitemid 350085864)
22. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother. 2001;12:133-150. (Pubitemid 32963913)
23. Shankar P, Russo M, Harnisch B, et al. Impaired function of circulating HIV-specific CD8 (+) T cells in chronic human immunodeficiency virus infection. Blood. 2000;96:3094-3101.
24. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450. (Pubitemid 27509814)
25. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest. 1994;93:768-775. (Pubitemid 24072820)
26. Maek-A-Nantawat W, Buranapraditkun S, Klaewsongkram J, et al. Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol. 2007;20:66-75. (Pubitemid 46608953)
27. Maertzdorf J, Osterhaus AD, Verjans GM. IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J Immunol. 2002;169:5897-5903. (Pubitemid 35291695)
28. Newcomb DC, Zhou W, Moore ML, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol. 2009;182:5317-5321.
29. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;11:1123-1132. (Pubitemid 41541790)
30. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8:369-377. (Pubitemid 46745412)
31. Blanpain C, Migeotte I, Lee B, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood. 1999;94:1899-1905. (Pubitemid 29430405)
32. Ogilvie P, Bardi G, Clark-Lewis I, et al. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood. 2001;97:1920-1924. (Pubitemid 32239067)
33. Cocchi F, De Vico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
34. Rebbapragada A, Wachihi C, Pettengeli C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589-598.
35. Amara A, Gall SL, Schwartz O, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. 1997;186:139-146. (Pubitemid 27304856)
36. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science. 1994;265:244-248.
37. Annunziato F, Galli G, Nappi F, et al. Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta. Blood. 2000;95:1167-1174. (Pubitemid 30099822)
38. Schrum S, Probst P, Fleischer B, et al. Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol. 1996;157:3598-3604. (Pubitemid 126449174)